Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05698017
PHASE1

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

Sponsor: Cytora Ltd.

View on ClinicalTrials.gov

Summary

Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)

Official title: Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300

Key Details

Gender

All

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2022-11-07

Completion Date

2026-02-19

Last Updated

2025-01-29

Healthy Volunteers

No

Interventions

BIOLOGICAL

hOMSC300

Human Oral Mucosa Stem Cells

Locations (1)

Tel-Aviv Sourasky Medical Center (Ichilov)

Tel Aviv, Israel